Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC

NCT07233668 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

172

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma ( mRCC)

Interventions

DRUG: Ipilimumab plus Nivolumab
PROCEDURE: Cytoreductive Nephrectomy

Sponsor

Seoul National University Hospital